IFNB1 and depressive disorder: Many factors that contribute to poor adherence to long-term therapy in patients with MS are recognised; [6] indeed, recent retrospective [7, 20] and prospective [19] observational studies indicate that the most common reasons to discontinue IFN-β therapy in real-world settings are adverse events (such as influenza-like symptoms, depression and injection-site reactions) and increased disease activity (including radiographic progression, relapses, and disability progression).